Effect of Danzhatongmai Pill on Coronary Atherosclerotic Heart Disease with Phlegm and Blood Stasis
Objective:To analyze the efficacy of Danzhatongmai Pill in the adjuvant treatment of coronary atherosclerotic heart disease with phlegm and blood stasis.Methods:From April 2020 to December 2022,60 patients with coronary atherosclerotic heart disease with phlegm and blood stasis were selected as the study subjects.Randomly divide patients into a control group and an observation group,with 30 cases in each group.The control group received routine intervention treatment,while the observation group received Danzhatongmai Pill in addition to the control group.After 8 weeks of treatment,analyze and compare the cardiac function status of the two groups,including ventricular septal thickness,left ventricular posterior wall end diastolic thickness,left ventricular end systolic diameter,stroke volume,left ventricular end diastolic diameter,left ventricular ejection fraction,traditional Chinese medicine syndrome score,and treatment efficacy.Result:After treatment,the TCM syndrome scores of both groups decreased compared to before treatment(P<0.05),and the TCM syndrome scores of the observation group were significantly lower than those of the control group(P<0.05).After treatment,the various cardiac function indicators of the observation group were significantly better than those of the control group(P<0.05),and the cardiac function indicators of the observation group were significantly lower than those of the control group(P<0.05).The effective rate of 83.3%in the observation group after treatment was significantly higher than that of 66.7%in the control group(P<0.05).Conclusion:Danzhatongmai Pill can improve the clinical symptoms of patients with coronary atherosclerotic heart disease of phlegm and blood stasis type,improve the cardiac function,and improve the therapeutic effect.
Danzhatongmai PillPhlegm and blood stasis intertwined typeCoronary atherosclerosisCardiac function indicators
NETL
NSTL
万方数据
